Physician profile
John M Canio
NPI 1598804346
$13,188.42
in general payments reported to CMS, 2019-2025
42 companies · $3,067 in 2025
The $3,067 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $1,159 · 2021: $984 · 2022: $2,115 · 2023: $1,947 · 2024: $2,203 · 2025: $3,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,142 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,141.62 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,756.87 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,060.97 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $987.83 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $887.88 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Madrigal Pharmaceuticals | $566.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $553.75 | 2022-2025 | |
| Celgene Corporation | $522.60 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $450.74 | 2021-2023 | |
| Pfizer INC. | $422.90 | 2019-2025 | |
| Qol Medical, LLC | $390.93 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $342.88 | 2019-2023 | Dificid |
| Gilead Sciences, INC. | $320.81 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $245.27 | 2024-2025 | Vowst, Zenpep |
| Endogastric Solutions, INC | $232.29 | 2022-2024 | Esophyx |
| Phathom Pharmaceuticals, INC. | $212.60 | 2024-2025 | Voquezna |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $153.35 | 2020-2024 | Ocaliva |
| Romark Laboratories, Lc | $130.67 | 2019-2020 | |
| Lilly USA, LLC | $115.55 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $73.56 | 2020-2022 | |
| Braintree Laboratories, INC. | $71.57 | 2019-2023 | Sutab |
| Fresenius Kabi USA, LLC | $67.79 | 2023-2024 | Idacio |
| Daiichi Sankyo INC. | $55.87 | 2020-2023 | Injectafer |
| Sandoz INC. | $50.17 | 2023 | Hyrimoz |
| Echosens North America, INC. | $46.93 | 2024 | Fibroscan |
| Boston Scientific Corporation | $46.75 | 2019-2023 | Radial Jaw 4 |
| Novo Nordisk INC | $45.65 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $44.20 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $41.46 | 2019-2022 | |
| Ardelyx, INC. | $39.65 | 2022-2024 | Ibsrela |
| Alfasigma USA, INC. | $30.24 | 2020 | |
| Organon LLC | $26.59 | 2022 | |
| Celltrion USA INC. | $24.37 | 2025 | Vegzelma |
| Laborie Medical Technologies Corp. | $22.82 | 2024 | |
| Mallinckrodt Hospital Products INC. | $21.11 | 2024 | Terlivaz |
| Shionogi INC | $20.83 | 2019 | |
| Allergan, INC. | $18.54 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.09 | 2019 | |
| Capsovision, INC. | $15.32 | 2025 | Capsocam Plus |
| Olympus America INC. | $15.07 | 2024 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Ferring Pharmaceuticals INC. | $14.51 | 2024 | Rebyota |
| Exact Sciences Corporation | $12.95 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $10.89 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Canio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.